Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance
Open Access
- 1 February 1997
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 75 (4) , 608-613
- https://doi.org/10.1038/bjc.1997.107
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Altered Pharmacokinetics of Vinblastine in Mdr1a P-glycoprotein-Deficient MiceJNCI Journal of the National Cancer Institute, 1996
- Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancersBritish Journal of Cancer, 1995
- Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.Journal of Clinical Oncology, 1995
- Preclinical pharmacology of 1069C85, a novel tubulin binderCancer Chemotherapy and Pharmacology, 1994
- High-performance liquid chromatographic assay for the measurement of the novel microtubule inhibitor 1069C85 in biological tissues and fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Modulation of multidrug-resistant multiple myeloma by cyclosporinThe Lancet, 1992
- P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.Journal of Clinical Oncology, 1991
- Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.Journal of Clinical Oncology, 1990
- Reversal of drug‐resistance in multiple myeloma with verapamilBritish Journal of Haematology, 1988